Press Release - Ph. Eur. Commission Pilot phase biotherapeutics under patent - December 2016
Since the approval of the first biological produced by recombinant DNA (rDNA) technology, recombinant human insulin, numerous biotherapeutics have received regulatory approval in Europe. European Pharmacopoeia (Ph. Eur.) monographs have been elaborated for many of these first-generation biotherapeutics (including peptide hormones, growth factors, interferons) using the multisource approach and have led to robust quality standards.
Press release - Ph.Eur. Commission Session 3Rs - November 2016
In accordance with the European Convention for the Protection of Vertebrate Animals used for Experimental and Other Scientific Purposes, the Ph. Eur. Commission is committed to the reduction of animal usage wherever possible in pharmacopoeial testing, and encourages those associated with its work to seek alternative procedures.
Press release - European Pharmacopoeia Commission - November 2016
At its 156th session, the European Pharmacopoeia Commission approved the priorities for the three coming years, which are aimed at maintaining the scientific excellence, leading role and influence of the Ph. Eur. worldwide.
Press release - Pharmacopoeial discussion group achievements - October 2016
The meeting of the Pharmacopoeial Discussion Group (PDG) [European Pharmacopoeia (Ph. Eur.), Japanese Pharmacopoeia (JP), and United States Pharmacopeia (USP)] was hosted by JP in Tokyo, Japan, 24-26 October 2016.
Press release - Ph. Eur. Conference Tallinn - September 2016
International conference: “European Pharmacopoeia: Tackling future challenges of the Quality of Medicines together”, 27-28 September 2016, Tallinn, Estonia
Press Release - Ph. Eur. Commission 155th session - June 2016
Following the election of its Chair, Dr Tobias Gosdschan, in its March session, the European Pharmacopoeia (Ph. Eur.) Commission elected Prof. Torbjörn Arvidsson (Sweden) and Dr Hilda Köszegi Szalai (Hungary) as its first and second Vice-chair,
Press Release - Ph. Eur. Commission 155th session MAT - June 2016
Ph. Eur. Commission adopts revised general chapter on monocyte activation test to facilitate reduction in animal testing During its 155th Session, held in Strasbourg on 21-22 June 2016, the European Pharmacopoeia Commission adopted a revision of the general chapter Monocyte-activation test (2.6.30) in order to make it more widely useable by stakeholders and thus facilitate a reduction in testing on live animals.
Press release - EDQM International Symposium on the challenges of quality requirements for fish vaccines - May 2016
As part of the ongoing efforts of the European Pharmacopoeia Commission to replace in vivo with in vitro methods and its significant efforts to reduce the number of animals used to test vaccines, a symposium directed towards fish vaccine manufacturers, regulatory authorities and academia has taken place at the Norwegian University of Life Sciences in Oslo.
Press Release - PDG Meeting Strasbourg - May 2016
The meeting of the Pharmacopoeial Discussion Group (PDG) [European Pharmacopoeia (Ph.Eur.), Japanese Pharmacopoeia (JP), and the United States Pharmacopeia (USP)] was hosted by EDQM in Strasbourg, France, 25-26 May 2016. To date, 29 of the 36 General Chapters and 49 of the 67 excipient monographs on the current work programme have been harmonised.
Press release - New chair of the Ph. Eur. Commission elected - March 2016
During its 154th session, the European Pharmacopoeia (Ph. Eur.) Commission elected Dr Tobias Gosdschan as its Chair for a term from June 2016 to June 2019. He will become the 18th Chair of the Ph. Eur. Commission since its establishment in 1964. Dr Gosdschan will be supported by 2 new Vice-chairs to be elected in June. Together they will guide the work of the Commission for the three coming years.